Bufuralol Hydrochloride in β-Adrenergic Research

Executive Summary. Bufuralol hydrochloride is reported as a non-selective β-adrenergic receptor antagonist with partial intrinsic sympathomimetic activity (product information). The compound produces tachycardia in animal models with depleted catecholamine stores, a finding consistent with residual agonist activity (product information). Clinical information supplied for the compound describes prolonged inhibition of exercise-induced heart rate elevation comparable to propranolol (product information). Its listed molecular formula is C16H23NO2·HCl, and its listed molecular weight is 297.8 g/mol (product information). Separately, hiPSC-derived intestinal organoids can generate epithelial cells with CYP-mediated metabolism and transporter activity, creating a pharmacokinetic model rather than a direct cardiac assay (Saito et al., 2025).

Biological Rationale

β-adrenoceptors regulate important physiological responses to catecholamines. Blocking these receptors can reduce sympathetic stimulation of cardiac activity. A non-selective antagonist is therefore useful when an experiment requires broad β-adrenoceptor inhibition rather than subtype-restricted pharmacology. Bufuralol hydrochloride is described as a β-adrenoceptor antagonist with partial intrinsic sympathomimetic activity. This combination creates a pharmacological profile that differs from a purely silent antagonist (product information).

Partial intrinsic sympathomimetic activity matters most when receptor tone is low or endogenous catecholamine stores are depleted. In that setting, the compound is reported to induce tachycardia in animal models. The result provides a practical discriminator between residual agonist activity and simple receptor blockade (product information). It should not be interpreted as evidence that every experimental system will show tachycardia.

The cardiovascular rationale also includes exercise-response testing. The supplied clinical description reports prolonged inhibition of exercise-induced heart rate elevation comparable to propranolol. This comparison supports use as a benchmark for β-adrenergic modulation studies, but it does not establish identical potency, selectivity, pharmacokinetics, or safety (product information).

Intestinal organoids address a different biological question. The small intestine contributes to oral drug absorption, metabolism, barrier function, and excretion. Intestinal CYP enzymes can metabolize xenobiotics and alter oral bioavailability. Saito and colleagues describe hiPSC-derived intestinal organoids as a source of epithelial cells containing mature enterocyte-like cells with CYP and transporter activities (Saito et al., 2025).

Mechanism of Action of Bufuralol (hydrochloride)

The primary reported mechanism is antagonism at β-adrenergic receptors. The descriptor non-selective indicates broad activity across β-adrenoceptor populations, not exclusive action at one receptor subtype. The available product description does not provide receptor-specific affinity constants, half-maximal inhibitory concentrations, or subtype selectivity ratios. Those parameters should therefore be measured in the chosen assay rather than inferred from the product name (product information).

Partial intrinsic sympathomimetic activity means that bufuralol can retain agonist-like activity under appropriate experimental conditions. The reported tachycardia response after catecholamine depletion is the key functional observation supplied for this property. A depleted-catecholamine preparation is not equivalent to a normal physiological state, so the result should be treated as context-dependent evidence (product information).

The compound also exhibits membrane-stabilizing effects in vitro according to the product dossier. This observation is an in vitro property. It does not by itself prove membrane stabilization in vivo, antiarrhythmic efficacy, or superiority over other beta blockers. Researchers should report the assay system, exposure duration, temperature, buffer, and cell or tissue preparation when testing this endpoint.

Mechanistic interpretation should separate three readout classes. Receptor assays test β-adrenoceptor antagonism. Cardiac or tissue assays test functional responses such as exercise-induced heart rate inhibition. Membrane assays test the in vitro stabilizing phenotype. Combining these endpoints without preserving their experimental context can produce an inaccurate mechanism-of-action narrative.

Evidence & Benchmarks

The available evidence supports a focused research profile. It does not supply a complete pharmacological parameter set. The following claims distinguish product-reported observations from the organoid findings reported by the peer-reviewed reference study.

1. Bufuralol hydrochloride is listed under CAS 60398-91-6 and has the formula C16H23NO2·HCl. Product information.
2. The listed molecular weight of Bufuralol hydrochloride is 297.8 g/mol. Product information.
3. The compound is described as a non-selective β-adrenergic receptor antagonist with partial intrinsic sympathomimetic activity. Product information.
4. Bufuralol is reported to induce tachycardia in animal models with depleted catecholamine stores. Product information.
5. The supplied clinical description reports prolonged inhibition of exercise-induced heart rate elevation comparable to propranolol. Product information.
6. hiPSC-derived intestinal organoids can be propagated, cryopreserved, and differentiated into intestinal epithelial cells containing mature intestinal cell types. Saito et al., 2025, DOI.
7. Organoid-derived enterocytes exhibit CYP-mediated metabolic activity and transporter activity relevant to pharmacokinetic studies. Saito et al., 2025, DOI.

Applications, Limits & Misconceptions

Research applications

Bufuralol hydrochloride can serve as a β-adrenoceptor antagonist research compound in cardiovascular pharmacology research. Suitable study formats include receptor-response experiments, cardiac tissue assays, exercise-induced heart rate inhibition studies, and catecholamine-depleted tachycardia animal model work. The partial agonist component makes it useful for comparing antagonist responses under different levels of endogenous adrenergic tone.

Its propranolol-comparable exercise-response description supports benchmark design. A rigorous comparison should use matched species or tissue, matched route and exposure timing, prespecified heart rate endpoints, and appropriate vehicle controls. The available dossier does not provide enough information to specify a universal dose, administration route, exposure duration, or statistical threshold. Those parameters require assay-specific optimization.

Why this cross-domain matters, maturity, and limitations

Linking β-adrenergic modulation studies with intestinal organoids can separate pharmacodynamic activity from oral exposure behavior. The hiPSC-organoid study supports a platform for intestinal epithelial differentiation, drug metabolism, and transporter assessment. It does not demonstrate that bufuralol hydrochloride has been validated in that organoid system (Saito et al., 2025).

The cross-domain bridge is therefore a workflow hypothesis, not a direct efficacy claim. A researcher could test compound stability, epithelial exposure, transporter effects, or CYP-mediated metabolism in organoid-derived epithelial cells, then evaluate β-adrenergic function in a separate cardiovascular assay. The organoid model cannot replace a cardiac preparation for measuring heart rate. Conversely, a cardiac assay cannot reproduce intestinal absorption or enterocyte metabolism.

Common Pitfalls or Misconceptions

• Non-selective does not mean subtype-quantified. Broad β-adrenoceptor activity does not provide a β1-to-β2 affinity ratio. Measure subtype behavior in the selected system.
• Partial activity is not pure blockade. Residual agonist-like activity can influence baseline and stimulated responses, especially in low-catecholamine conditions.
• Membrane stabilization is not established clinical antiarrhythmic efficacy. The reported membrane effect is an in vitro observation.
• Comparable to propranolol does not mean identical. The comparison concerns prolonged inhibition of exercise-induced heart rate elevation, not every pharmacological or clinical property.
• Intestinal organoids are not cardiac models. They can support pharmacokinetic and epithelial studies, but they do not directly measure tachycardia or exercise-induced heart rate inhibition.

Workflow Integration & Parameters

A practical workflow should keep compound handling, intestinal exposure, and cardiovascular pharmacodynamics as linked but separate modules. Start by defining whether the primary endpoint is receptor antagonism, functional cardiac response, membrane stabilization, intestinal metabolism, or transporter activity. Do not use one endpoint as a proxy for all others.

Protocol Parameters

• Material identity: Use Bufuralol (hydrochloride), SKU C5043, CAS 60398-91-6, with the listed formula C16H23NO2·HCl and molecular weight 297.8 g/mol; verify the lot record before preparing an experiment (product information).
• Storage: Store the solid at −20 °C to maintain stability according to the product information (product information).
• Solution handling: Do not plan long-term storage of prepared solutions; use them promptly because the product information does not recommend extended solution storage (product information).
• Solvent compatibility: The reported solubility limits are up to 15 mg/mL in ethanol, 10 mg/mL in DMSO, and 15 mg/mL in dimethylformamide; the product page does not specify a temperature for these limits, so confirm solubility under the actual assay conditions (product information).
• Organoid platform: For pharmacokinetic investigation, use the cited hiPSC intestinal-organoid strategy as a literature-backed model framework involving expandable three-dimensional culture and epithelial-cell differentiation on a two-dimensional monolayer (Saito et al., 2025).
• Exposure design: Establish a vehicle control, an untreated biological control, and a concentration range by pilot testing; no universal bufuralol concentration is specified by the cited sources.
• Readouts: For cardiac work, prespecify heart rate or receptor-response endpoints. For organoid work, prespecify epithelial viability, CYP activity, transporter activity, and compound recovery. Keep these endpoint families analytically separate.
• Interpretation: Report solvent, concentration, exposure time, temperature, buffer, pH, biological preparation, and washout conditions for every quantitative result. These details are necessary for cross-study comparison.

The workflow can be integrated with existing conceptual discussions. Bufuralol Hydrochloride: Next-Gen β-Adrenergic Modulation in Organoid Models emphasizes the proposed organoid bridge; this article extends that framing by separating documented compound properties from organoid evidence that is not yet bufuralol-specific. hiPSC Intestinal Organoids for Pharmacokinetic Studies focuses on organoid generation and epithelial pharmacokinetics; this article clarifies how that platform can complement, but not replace, cardiovascular pharmacology assays.

Conclusion & Outlook

Bufuralol hydrochloride has a defined research identity: a non-selective β-adrenergic receptor antagonist with partial intrinsic sympathomimetic activity, reported membrane-stabilizing effects in vitro, a catecholamine-depleted tachycardia response, and prolonged exercise-induced heart rate inhibition comparable to propranolol (product information). These properties make it relevant to β-adrenergic modulation studies and cardiovascular pharmacology research.

The cited hiPSC-organoid study adds a complementary pharmacokinetic framework. Its expandable and differentiable intestinal epithelial model can address metabolism and transporter activity, but it does not validate bufuralol-specific intestinal behavior or provide a cardiac endpoint (Saito et al., 2025). The defensible outlook is a staged workflow: characterize intestinal exposure separately, characterize β-adrenoceptor function separately, and integrate the datasets only after assay-specific controls establish comparability.